Literature DB >> 23289024

When the FRAX(®) test is applied to controlled clinical trials.

Carmelo Erio Fiore1, Agostino Gaudio.   

Abstract

FRAX(®) is a computer-based algorithm developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases in Sheffield (UK). This algorithm calculates fracture probability from easily obtained clinical risk factors in men and women: age, sex, body mass index and dichotomized variables comprising prior fragility fracture, parental history of hip fracture, current tobacco smoking, use of long-term oral glucocorticoid, rheumatoid arthritis, other causes of secondary osteoporosis and high alcohol consumption (femoral neck bone mineral density can be optionally input to enhance fracture risk prediction). The output of FRAX(®) is the 10-year probability of a major osteoporotic fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture.Recently various Authors have re-evaluated the effectiveness of drugs approved for postmenopausal osteoporosis to test whether they are more effective in women with higher FRAX(®) probabilities.

Entities:  

Keywords:  FRAX®; alendronate; bazedoxifene; clodronate; denosumab; raloxifene; strontium ranelate

Year:  2012        PMID: 23289024      PMCID: PMC3535994     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  15 in total

1.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-02-02       Impact factor: 4.507

2.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Authors:  J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

Review 3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

4.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

5.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Authors:  P D Delmas; H K Genant; G G Crans; J L Stock; M Wong; E Siris; J D Adachi
Journal:  Bone       Date:  2003-10       Impact factor: 4.398

6.  The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.

Authors:  Naibedya Chattopadhyay; Stephen J Quinn; Olga Kifor; Chianping Ye; Edward M Brown
Journal:  Biochem Pharmacol       Date:  2007-04-27       Impact factor: 5.858

7.  The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Authors:  Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

8.  From relative risk to absolute fracture risk calculation: the FRAX algorithm.

Authors:  Eugene V McCloskey; Helena Johansson; Anders Oden; John A Kanis
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

9.  Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.

Authors:  E V McCloskey; H Johansson; A Oden; S Vasireddy; K Kayan; K Pande; T Jalava; J A Kanis
Journal:  Osteoporos Int       Date:  2008-11-11       Impact factor: 4.507

Review 10.  Interpretation and use of FRAX in clinical practice.

Authors:  J A Kanis; D Hans; C Cooper; S Baim; J P Bilezikian; N Binkley; J A Cauley; J E Compston; B Dawson-Hughes; G El-Hajj Fuleihan; H Johansson; W D Leslie; E M Lewiecki; M Luckey; A Oden; S E Papapoulos; C Poiana; R Rizzoli; D A Wahl; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-07-21       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.